Osel, Inc.’s Lead Product LACTIN-V Enters Phase 2b Study to Prevent Recurrence of Bacterial Vaginosis

Mountain View, CA (May 11, 2016): Osel, Inc. today announced the initiation of a Phase 2b clinical study of its lead product candidate, LACTIN-V, to prevent the recurrence of bacterial vaginosis following antibiotic therapy. LACTIN-V is a live biotherapeutic product that contains a naturally occurring Lactobacillus strain that is part of the vaginal microbiome of healthy women and used to restore the vaginal microbiota and prevent recurrence of infection.